OBJECTIVE: To determine the endocrine, neuropsychological and genetic features of a child with resistance to thyroid hormone (RTH), and his response to long-term triiodothyroacetic acid (TRIAC) therapy. METHODS: Growth, thyroid function, and neuropsychology were assessed at baseline and during 12-month TRIAC therapy. Genetic analysis was performed by PCR and denaturing high performance liquid chromatography. RESULTS: The main clinical finding was the attention deficit-hyperactivity disorder (ADHD). A novel mutation in exon 10 (phenylalanine to isoleucine in codon 455) was found. Long-term TRIAC therapy was effective in the management of the endocrine and neuropsychological manifestations of the syndrome. CONCLUSIONS: ADHD was the only phenotypic manifestation of this novel mutation of thyroid hormone (TH) receptor. TRIAC is an effective and safe drug in the long-term treatment of children with RTH.
OBJECTIVE: To determine the endocrine, neuropsychological and genetic features of a child with resistance to thyroid hormone (RTH), and his response to long-term triiodothyroacetic acid (TRIAC) therapy. METHODS: Growth, thyroid function, and neuropsychology were assessed at baseline and during 12-month TRIAC therapy. Genetic analysis was performed by PCR and denaturing high performance liquid chromatography. RESULTS: The main clinical finding was the attention deficit-hyperactivity disorder (ADHD). A novel mutation in exon 10 (phenylalanine to isoleucine in codon 455) was found. Long-term TRIAC therapy was effective in the management of the endocrine and neuropsychological manifestations of the syndrome. CONCLUSIONS:ADHD was the only phenotypic manifestation of this novel mutation of thyroid hormone (TH) receptor. TRIAC is an effective and safe drug in the long-term treatment of children with RTH.
Authors: B Russell Huber; Ben Sandler; Brian L West; Suzana T Cunha Lima; Hoa T Nguyen; James W Apriletti; John D Baxter; Robert J Fletterick Journal: Mol Endocrinol Date: 2003-01-16
Authors: Y Hayashi; R E Weiss; D H Sarne; P M Yen; T Sunthornthepvarakul; C Marcocci; W W Chin; S Refetoff Journal: J Clin Endocrinol Metab Date: 1995-11 Impact factor: 5.958
Authors: E Taylor; J Sergeant; M Doepfner; B Gunning; S Overmeyer; H J Möbius; H G Eisert Journal: Eur Child Adolesc Psychiatry Date: 1998-12 Impact factor: 4.785
Authors: P Beck-Peccoz; V K Chatterjee; W W Chin; L J DeGroot; J L Jameson; H Nakamura; S Refetoff; S J Usala; B D Weintraub Journal: Clin Endocrinol (Oxf) Date: 1994-05 Impact factor: 3.478
Authors: S Reutrakul; P M Sadow; S Pannain; J Pohlenz; G A Carvalho; P E Macchia; R E Weiss; S Refetoff Journal: J Clin Endocrinol Metab Date: 2000-10 Impact factor: 5.958
Authors: A A E Marcondes; T G B Gomez; T T Ravache; A Batistuzzo; F B Lorena; C S de Paula; R Lowenthal; A C Bianco; M O Ribeiro Journal: J Endocrinol Invest Date: 2021-01-15 Impact factor: 4.256